Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

This is a Healthy Liver, Healthy Lives (HLHL) symposium bringing the global community together to elevate liver disease as a global health priority.

The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) have jointly led a multi-stakeholder Consensus Process focused on the use of surrogate endpoints and real-world evidence in the design of clinical trials for Primary Biliary Cholangitis (PBC). This collaborative initiative culminated in a Consensus Conference held during the 2025 EASL Congress in Amsterdam, bringing together global experts, regulatory authorities, patient representatives, and industry stakeholders. This session will feature presentations of the final recommendations from this consensus process.

Researchers in this abstract parallel session will share the results of recent clinical trials in MASH.

The Hepatitis D Virus (HDV) is a defective small RNA virus that causes acute hepatitis, acute liver failure, and chronic hepatitis, often leading to rapid progression to cirrhosis and its complications. In this Community Conservation, we will review recent updates on the epidemiological data of HDV, the clinical course of HDV-related liver disease, and the challenges associated with HDV treatment.

As the landscape of liver disease evolves, so too must our tools for evaluating therapeutic efficacy and disease progression.  This cutting-edge session will explore the latest advances and ongoing debates surrounding clinical trial and real-world endpoints for metabolic dysfunction-associated alcohol-related liver disease (MetALD), alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), and alpha-1 antitrypsin deficiency (AATD). For MetALD, we will present the consensus endpoints developed by the AASLD/EASL MetALD Working Groups.  Experts will address the challenges of defining meaningful and harmonized endpoints across overlapping phenotypes, the role of biomarkers and imaging, and regulatory considerations in early- and late-phase trials. Emphasis will be placed on how to tailor endpoints to the unique pathophysiology of each disease while also considering patient-centered outcomes and emerging surrogate markers. This session is essential for clinicians, researchers, and industry stakeholders involved in trial design and drug development for liver diseases. 

This session will review the key events leading to the discovery of the Hepatitis B Virus (HBV), the global public health impact HBV has had on human health, the development of an effective vaccine to prevent transmission that has reduced incident infection in endemic regions, and the state of current elimination efforts. Faculty members will also cover the history of the development of therapy for HBV and the effectiveness of current therapy to prevent complications of chronic HBV infection. Finally, new therapies in development for a cure for chronic HBV infection will be reviewed.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.